Defense Secretary Pete Hegseth has ordered mandatory testosterone screening for all active duty and reserve military personnel aged 30 and older, effective during annual health assessments. Soldiers under 30 can request screening voluntarily. The policy affects hundreds of thousands of service members.
Hegseth framed the initiative around combat readiness, citing 'performance,' 'resilience,' and 'the biological foundation required to sustain the fight.' He claimed it is not about artificial enhancement and that treatment can be declined. Doctors disagree with the framing. The clinical literature on testosterone therapy in men without confirmed hypogonadism shows limited benefit and real risks, including cardiovascular strain and fertility suppression.
The full Ars Technica piece goes beyond the policy announcement and into the medical argument: what testosterone screening actually catches, who genuinely benefits from treatment, and why endocrinologists are calling this a clinical minefield. The gap between Hegseth's language and the evidence is where the real story lives.
[READ ORIGINAL →]